Literature DB >> 15104524

Atypical antipsychotics in the treatment of children and adolescents: clinical applications.

Robert L Findling1, Nora K McNamara.   

Abstract

Atypical antipsychotics offer superior safety and similar efficacy compared with conventional agents in adults with psychotic disorders. Consequently, atypical antipsychotics have been increasingly used in children and adolescents. Because most information now available on pediatric use comes from case reports and small open-label studies rather than large controlled trials, treatment in pediatric patients is often guided by experience with adults or based on limited evidence in youths. Although the literature contains reports on the use of each agent in this class in children, risperidone has been the focus of the greatest number of reports. However, the atypical antipsychotics are not interchangeable; each has a unique pharmacologic profile and may differ considerably in terms of adverse effects. Evidence on the use of atypical antipsychotics in children and adolescents is summarized in this review.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15104524

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  18 in total

1.  Effects of risperidone on dopamine receptor subtypes in developing rat brain.

Authors:  Taylor Moran-Gates; Christopher Grady; Young Shik Park; Ross J Baldessarini; Frank I Tarazi
Journal:  Eur Neuropsychopharmacol       Date:  2006-12-18       Impact factor: 4.600

2.  Factors influencing adherence in children and adolescents treated with antipsychotics or antidepressants.

Authors:  Kurosch Yazdi; Gabriele Unterlass; Georg Kemmler; Karl Kralovec; Wolfgang Aichhorn
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

3.  Effects of repeated risperidone exposure on serotonin receptor subtypes in developing rats.

Authors:  Yong Kee Choi; Taylor Moran-Gates; Matthew P Gardner; Frank I Tarazi
Journal:  Eur Neuropsychopharmacol       Date:  2009-10-29       Impact factor: 4.600

4.  Trends, correlates, and disease patterns of antipsychotic use among children and adolescents in Taiwan.

Authors:  Yuan-Chang Hsu; I-Chia Chien; Happy Kuy-Lok Tan; Ching-Heng Lin; Shu-Wen Cheng; Yiing-Jenq Chou; Pesus Chou
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2013-05-08       Impact factor: 4.328

5.  Prevalence of movement disorders in adolescent patients with schizophrenia and in relationship to predominantly atypical antipsychotic treatment.

Authors:  Stefan Gebhardt; Fabian Härtling; Markus Hanke; Markus Mittendorf; Frank M Theisen; Karin Wolf-Ostermann; Phillip Grant; Matthias Martin; Christian Fleischhaker; Eberhard Schulz; Helmut Remschmidt
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-04-28       Impact factor: 4.785

6.  Treatment of ADHD in patients with bipolar disorder.

Authors:  Rachel Girard; Ridha Joober
Journal:  J Psychiatry Neurosci       Date:  2017-11       Impact factor: 6.186

7.  Long-acting Injectable Risperidone Use in an 11-Years-Old Bipolar Child.

Authors:  Sevcan Karakoç Demirkaya; Süleyman Salih Zoroğlu
Journal:  Noro Psikiyatr Ars       Date:  2016-04-15       Impact factor: 1.339

Review 8.  Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology.

Authors:  Oliver D Howes; Maria Rogdaki; James L Findon; Robert H Wichers; Tony Charman; Bryan H King; Eva Loth; Gráinne M McAlonan; James T McCracken; Jeremy R Parr; Carol Povey; Paramala Santosh; Simon Wallace; Emily Simonoff; Declan G Murphy
Journal:  J Psychopharmacol       Date:  2017-12-14       Impact factor: 4.153

Review 9.  Safety and pharmacokinetics of atypical antipsychotics in children and adolescents.

Authors:  Silvio Caccia
Journal:  Paediatr Drugs       Date:  2013-06       Impact factor: 3.022

10.  Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder. An open label maintenance study.

Authors:  Ozlem Gencer; F Neslihan Inal Emiroglu; Suha Miral; Burak Baykara; Aysen Baykara; Eray Dirik
Journal:  Eur Child Adolesc Psychiatry       Date:  2008-06       Impact factor: 4.785

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.